Literature DB >> 26169437

Maternal Consequences of the Detection of Fragile X Carriers in Newborn Screening.

Donald B Bailey1, Anne Wheeler2, Elizabeth Berry-Kravis3, Randi Hagerman4, Flora Tassone4, Cynthia M Powell5, Myra Roche5, Louise W Gane6, John Sideris7.   

Abstract

OBJECTIVES: The possibility of newborn screening for fragile X syndrome is complicated by the potential for identifying premutation carriers. Although knowing the child's carrier status has potential benefits, the possibility of late-onset disorders in carrier children and their parents raises concerns about whether such information would be distressing to parents and potentially more harmful than helpful. This study sought to answer this question by offering voluntary fragile X screening to new parents and returning results for both the full mutation and premutation FMR1 gene expansions. We tested the assumption that such information could lead to adverse mental health outcomes or decision regret. We also wanted to know if child age and spousal support were associated with the outcomes of interest.
METHODS: Eighteen mothers of screen-positive infants with the premutation and 15 comparison mothers completed a battery of assessments of maternal anxiety, postpartum depression, stress, family quality of life, decision regret, and spousal support. The study was longitudinal, with an average of 3 assessments per mother.
RESULTS: The premutation group was not statistically different from the comparison group on measures of anxiety, depression, stress, or quality of life. A subset of mothers experienced clinically significant anxiety and decision regret, but factors associated with these outcomes could not be identified. Greater spousal support was generally associated with more positive outcomes.
CONCLUSIONS: Although we did not find evidence of significant adverse events, disclosure of newborn carrier status remains an important consideration in newborn screening policy.
Copyright © 2015 by the American Academy of Pediatrics.

Entities:  

Mesh:

Year:  2015        PMID: 26169437      PMCID: PMC4516945          DOI: 10.1542/peds.2015-0414

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  41 in total

1.  High rates of comorbid depressive and anxiety disorders among women with premutation of the FMR1 gene.

Authors:  Heather A Kenna; Molly Tartter; Scott S Hall; Amy A Lightbody; Quynh Nguyen; C Paula de los Angeles; Allan L Reiss; Natalie L Rasgon
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2013-09-03       Impact factor: 3.568

2.  Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication.

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Kathleen R Merikangas; Ellen E Walters
Journal:  Arch Gen Psychiatry       Date:  2005-06

3.  Failure of hearing screening in high-risk neonates does not increase parental anxiety.

Authors:  A Suppiej; E Cainelli; M De Benedittis; E Rizzardi; P S Bisiacchi; M Ermani; E Orzan; V Zanardo
Journal:  J Matern Fetal Neonatal Med       Date:  2013-02-12

Review 4.  Anxious and depressive components of Edinburgh Postnatal Depression Scale in maternal postpartum psychological problems.

Authors:  Angela Petrozzi; Luigi Gagliardi
Journal:  J Perinat Med       Date:  2013-07       Impact factor: 1.901

5.  Maternal anxiety associated with newborn genetic screening for type 1 diabetes.

Authors:  Suzanne Bennett Johnson; Amy E Baughcum; Stacy K Carmichael; Jin-Xiong She; Desmond A Schatz
Journal:  Diabetes Care       Date:  2004-02       Impact factor: 19.112

6.  Postpartum anxiety and maternal-infant health outcomes.

Authors:  Ian M Paul; Danielle S Downs; Eric W Schaefer; Jessica S Beiler; Carol S Weisman
Journal:  Pediatrics       Date:  2013-03-04       Impact factor: 7.124

7.  Caregiver opinions about fragile X population screening.

Authors:  Donald B Bailey; Ellen Bishop; Melissa Raspa; Debra Skinner
Journal:  Genet Med       Date:  2011-09-13       Impact factor: 8.822

8.  Can a decision aid enable informed decisions in neonatal nursery recruitment for a fragile X newborn screening study?

Authors:  Donald B Bailey; Carla Bann; Ellen Bishop; Sonia Guarda; Leah Barnum; Myra Roche
Journal:  Genet Med       Date:  2012-10-25       Impact factor: 8.822

9.  Male carriers of the FMR1 premutation show altered hippocampal-prefrontal function during memory encoding.

Authors:  John M Wang; Kami Koldewyn; Ryu-Ichiro Hashimoto; Andrea Schneider; Lien Le; Flora Tassone; Katherine Cheung; Paul Hagerman; David Hessl; Susan M Rivera
Journal:  Front Hum Neurosci       Date:  2012-10-30       Impact factor: 3.169

10.  FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States.

Authors:  Flora Tassone; Ka Pou Iong; Tzu-Han Tong; Joyce Lo; Louise W Gane; Elizabeth Berry-Kravis; Danh Nguyen; Lisa Y Mu; Jennifer Laffin; Don B Bailey; Randi J Hagerman
Journal:  Genome Med       Date:  2012-12-21       Impact factor: 11.117

View more
  4 in total

1.  The effects of optimism, religion, and hope on mood and anxiety disorders in women with the FMR1 premutation.

Authors:  E P Lowell; B L Tonnsen; D B Bailey; J E Roberts
Journal:  J Intellect Disabil Res       Date:  2017-10

2.  Developmental profiles of infants with an FMR1 premutation.

Authors:  Anne C Wheeler; John Sideris; Randi Hagerman; Elizabeth Berry-Kravis; Flora Tassone; Donald B Bailey
Journal:  J Neurodev Disord       Date:  2016-11-03       Impact factor: 4.025

3.  Brain and behavior development in autism from birth through infancy.

Authors:  Mark D Shen; Joseph Piven
Journal:  Dialogues Clin Neurosci       Date:  2017-12       Impact factor: 5.986

4.  Extent and Predictors of Decision Regret among Informal Caregivers Making Decisions for a Loved One: A Systematic Review.

Authors:  Hélène Elidor; Rhéda Adekpedjou; Hervé Tchala Vignon Zomahoun; Ali Ben Charif; Titilayo Tatiana Agbadjé; Nathalie Rheault; France Légaré
Journal:  Med Decis Making       Date:  2020-10-22       Impact factor: 2.583

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.